TR - Tootsie Roll Industri... Stock Analysis | Stock Taper
Logo
Tootsie Roll Industries, Inc.

TR

Tootsie Roll Industries, Inc. NYSE
$42.23 0.60% (+0.25)

Market Cap $1.77 B
52w High $44.27
52w Low $29.13
Dividend Yield 0.95%
Frequency Quarterly
P/E 32.48
Volume 99.22K
Outstanding Shares 41.82M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $232.71M $45.51M $35.66M 15.32% $0.49 $53.47M
Q2-2025 $155.09M $44.36M $17.54M 11.31% $0.24 $16.73M
Q1-2025 $148.46M $29.39M $18.06M 12.16% $0.25 $27.63M
Q4-2024 $193.37M $36.89M $22.51M 11.64% $0.32 $70.05M
Q3-2024 $225.93M $41.83M $32.84M 14.54% $0.46 $39.8M

What's going well?

Revenue and profits surged, with net income and EPS both doubling. The company became much more efficient, holding expenses nearly flat while sales soared. No debt burden and strong bottom-line growth are big positives.

What's concerning?

Gross margins slipped, meaning costs are rising faster than sales. Some of the profit boost came from other income, not just the core business. Revenue swings suggest the business may be volatile.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $0 $0 $313.41M $940.97M
Q3-2025 $119.83M $1.23B $310.09M $918.85M
Q2-2025 $170.53M $1.18B $288.69M $893.13M
Q1-2025 $176.61M $1.14B $262.7M $879.35M
Q4-2024 $194.63M $1.15B $276.77M $870.74M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $35.65M $62.22M $-97.51M $-6.54M $-41.63M $50.67M
Q2-2025 $17.53M $-8.54M $9.34M $-184K $1.03M $-16.05M
Q1-2025 $18.04M $3.6M $-3.67M $-19.25M $-19.3M $750K
Q4-2024 $22.5M $68.79M $-3.67M $-17.87M $47.1M $64.7M
Q3-2024 $32.83M $61.33M $-6.26M $-8.63M $46.1M $55.84M

What's strong about this company's cash flow?

TR swung from burning cash to producing over $62 million from operations and $50.7 million in free cash flow. Profits are backed by real cash, and the company is not dependent on outside funding.

What are the cash flow concerns?

Cash balance dropped sharply due to large investments, and both inventory and receivables jumped, tying up cash. The big working capital benefit may not repeat.

Revenue by Products

Product Q1-2025Q2-2025Q3-2025Q4-2025
Product
Product
$150.00M $150.00M $230.00M $190.00M
Rental and Royalty
Rental and Royalty
$0 $0 $0 $0

5-Year Trend Analysis

A comprehensive look at Tootsie Roll Industries, Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

Key strengths include strong profitability, solid cash conversion, and a conservative capital structure with very little reliance on debt. The company’s portfolio of iconic, widely recognized candy brands, combined with efficient, highly automated manufacturing, underpins a durable cost and brand advantage. Regular dividends and ongoing reinvestment in plants and equipment further reinforce the perception of a stable, long-lived franchise in a defensive consumer segment.

! Risks

Main risks center on data uncertainty in the reported balance sheet, especially around liquidity and asset reporting, and on the strategic side, limited formal R&D and heavy dependence on legacy brands. The business is exposed to swings in ingredient costs and to gradual shifts toward healthier snacking and changing consumer preferences. Concentration in North America, intense competition from larger confectionery companies, and the possibility that incremental innovation may not be enough in a faster-changing market all add to the risk profile.

Outlook

Overall, Tootsie Roll looks like a mature, steady candy business with a strong brand foundation and dependable cash generation, but likely modest growth prospects. Its future path will probably be driven by incremental capacity expansions, international push, and careful brand refreshes rather than dramatic reinvention. The outlook is relatively stable as long as consumer demand for its core products remains resilient and the company continues to manage costs well, but the long-term trajectory will depend on how effectively it adapts to evolving health trends and global competition. Unusual balance sheet data means any forward view should be cross-checked against detailed filings for confirmation.